{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T08:03:01Z","timestamp":1751961781387,"version":"3.40.5"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2018-0132_s_999_w2aab3b7c61b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The approach to the clinical management of Graves\u2019 disease (GD) is debatable. This study aimed to identify predictors of remission in pediatric GD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0132_s_998_w2aab3b7c61b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A longitudinal study of 36 children and adolescents with GD followed from 1997 to 2017 at a single tertiary hospital was performed. Clinical and biochemical parameters, including comorbidities, treatment with anti-thyroid drugs (ATD) or definitive therapy (radioiodine [RIT] and thyroidectomy), and remission as the main outcome were collected. We performed a multivariable logistic regression analysis to identify likely predictors of remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0132_s_997_w2aab3b7c61b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among patients, most were female, in late puberty, with exuberant symptoms at onset. Eleven also suffered from Down syndrome (DS). Thirty-four patients (94%) started on methimazole from disease onset, and 25 (69%) received it as the only therapy, with a mean duration of 2.7\u00b11.8 years. Six changed to RIT and three underwent thyroidectomy; no DS patient received definitive therapy. Remission was higher in DS patients (45% vs. 25%, p=0.24), but afterwards (3.9\u00b12.5 vs. 2.3\u00b11.4 years, p&lt;0.05); there was no significance in relapsing (20% vs. 15%). Females were less likely to reach remission (p&lt;0.05); serum free thyroxine at onset was higher (p&lt;0.05) in patients who required definitive therapy. Thyroid-stimulating immunoglobulin (TSI) values normalized in exclusively ATD therapy, especially from 2 years on (p&lt;0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0132_s_996_w2aab3b7c61b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Males were more likely to achieve remission. TSI values may normalize in GD, notably from the second year of treatment. DS children may benefit with conservative management in GD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2018-0132","type":"journal-article","created":{"date-parts":[[2018,7,13]],"date-time":"2018-07-13T01:36:04Z","timestamp":1531445764000},"page":"743-750","source":"Crossref","is-referenced-by-count":9,"title":["Clinical management of childhood hyperthyroidism with and without Down syndrome: a longitudinal study at a single center"],"prefix":"10.1515","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9682-0289","authenticated-orcid":false,"given":"Tiago Jeronimo","family":"Dos Santos","sequence":"first","affiliation":[{"name":"Department of Endocrinology , Hospital Infantil Universitario Ni\u00f1o Jes\u00fas. Instituto de Investigaci\u00f3n La Princesa , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel \u00c1ngel","family":"Martos-Moreno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Hospital Infantil Universitario Ni\u00f1o Jes\u00fas. Instituto de Investigaci\u00f3n La Princesa , Madrid , Spain"},{"name":"Department of Pediatrics , Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"CIBER Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n. Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Mu\u00f1oz-Calvo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Hospital Infantil Universitario Ni\u00f1o Jes\u00fas. Instituto de Investigaci\u00f3n La Princesa , Madrid , Spain"},{"name":"Department of Pediatrics , Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"CIBER Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n. Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Pozo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , Hospital Infantil Universitario Ni\u00f1o Jes\u00fas. Instituto de Investigaci\u00f3n La Princesa , Madrid , Spain"},{"name":"Department of Pediatrics , Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"CIBER Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n. Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rodr\u00edguez-Artalejo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health , Universidad Aut\u00f3noma de Madrid\/IdiPaz , CIBER of Epidemiology and Public Health (CIBERESP) , Madrid , Spain"},{"name":"IMDEA Food Institute, CEIUAM+CSIC , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-0276","authenticated-orcid":false,"given":"Jes\u00fas","family":"Argente","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"CIBER Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n. Instituto de Salud Carlos III , Madrid , Spain"},{"name":"IMDEA Food Institute, CEIUAM+CSIC , Madrid , Spain"},{"name":"Department of Pediatrics and Pediatric Endocrinology , Hospital Infantil Universitario Ni\u00f1o Jes\u00fas. Instituto de Investigaci\u00f3n La Princesa , Av. Men\u00e9ndez Pelayo 65 , 28009 Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"key":"2023040100083367651_j_jpem-2018-0132_ref_001_w2aab3b7c61b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Kaguelidou F, Alberti C, Carel JC. Graves\u2019 disease in children. Best Pract Res Clin Endocrinol Metab 2014;28:233\u201343.","DOI":"10.1016\/j.beem.2013.08.008"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_002_w2aab3b7c61b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Hanley P, Lord K, Bauer AJ. Thyroid disorders in children and adolescents. JAMA Pediatr 2016;170:1008.","DOI":"10.1001\/jamapediatrics.2016.0486"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_003_w2aab3b7c61b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Srinivasan S, Misra M. Hyperthyroidism in children. Pediatr Rev 2015;36:239\u201348.","DOI":"10.1542\/pir.36.6.239"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_004_w2aab3b7c61b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Carl\u00e9 A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, et al. Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. Eur J Endocrinol 2011;164:801\u20139.","DOI":"10.1530\/EJE-10-1155"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_005_w2aab3b7c61b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132041.","DOI":"10.1186\/1687-9856-2009-132041"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_006_w2aab3b7c61b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol (Oxf) 2010;72:358\u201363.","DOI":"10.1111\/j.1365-2265.2009.03717.x"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_007_w2aab3b7c61b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Hemminki K, Li X, Sundquist J, Sundquist K. The epidemiology of Graves\u2019 disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010;34:J307\u201313.","DOI":"10.1016\/j.jaut.2009.11.019"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_008_w2aab3b7c61b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, Chillaron-Jordan JJ, Corretger JM, et al. Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol (Oxf) 2009;71:110\u20134.","DOI":"10.1111\/j.1365-2265.2008.03419.x"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_009_w2aab3b7c61b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Aversa T, Lombardo F, Corrias A, Salerno M, De Luca F, et al. In young patients with turner or down syndrome, Graves\u2019 disease presentation is often preceded by Hashimoto\u2019s thyroiditis. Thyroid 2014;24:744\u20137.","DOI":"10.1089\/thy.2013.0452"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_010_w2aab3b7c61b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17:456\u2013520.","DOI":"10.4158\/EP.17.3.456"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_011_w2aab3b7c61b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Rivkees SA. Controversies in the management of Graves\u2019 disease in children. J Endocrinol Invest 2016;39:1247\u201357.","DOI":"10.1007\/s40618-016-0477-x"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_012_w2aab3b7c61b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343\u2013421.","DOI":"10.1089\/thy.2016.0229"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_013_w2aab3b7c61b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, et al. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers. J Pediatr 2014;164:1189\u201394.","DOI":"10.1016\/j.jpeds.2013.12.047"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_014_w2aab3b7c61b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children*. J Clin Endocrinol Metab 1997;82:1719\u201326.","DOI":"10.1210\/jc.82.6.1719"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_015_w2aab3b7c61b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves\u2019 disease: a prospective, multicenter study. Pediatrics 2008;121:e481\u20138.","DOI":"10.1542\/peds.2007-1535"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_016_w2aab3b7c61b1b6b1ab2b2c16Aa","unstructured":"Weetman A, DeGroot LJ. Autoimmunity to the thyroid gland. South Dartmouth, MA: Endotext. MDText.com, Inc., 2000."},{"key":"2023040100083367651_j_jpem-2018-0132_ref_017_w2aab3b7c61b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves\u2019 disease treated using antithyroid medication. Thyroid 2007;17:1103\u20137.","DOI":"10.1089\/thy.2007.0072"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_018_w2aab3b7c61b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"De Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, et al. Peculiarities of Graves\u2019 disease in children and adolescents with Down\u2019s syndrome. Eur J Endocrinol 2010;162:591\u20135.","DOI":"10.1530\/EJE-09-0751"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_019_w2aab3b7c61b1b6b1ab2b2c19Aa","unstructured":"Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fern\u00e1ndez-Ramos C, et al. Growth Charts & Tables (translational and longitudinal study) [Curvas y tablas de crecimiento (estudio longitudinal y transversal)]. Available at: https:\/\/www.aepap.org\/sites\/default\/files\/curvas_orbegozo.pdf ."},{"key":"2023040100083367651_j_jpem-2018-0132_ref_020_w2aab3b7c61b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976;51:170\u20139.","DOI":"10.1136\/adc.51.3.170"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_021_w2aab3b7c61b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Kaguelidou F, Carel JC, L\u00e9ger J. Graves\u2019 disease in childhood: advances in management with antithyroid drug therapy. Horm Res Paediatr 2009;71:310\u20137.","DOI":"10.1159\/000223414"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_022_w2aab3b7c61b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Weetman AP. Graves\u2019 hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2006;2:2\u20133.","DOI":"10.1038\/ncpendmet0068"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_023_w2aab3b7c61b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Abraham P, Avenell A, Watson W, Park C, Bevan J. Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev 2010;20:CD003420.","DOI":"10.1002\/14651858.CD003420.pub4"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_024_w2aab3b7c61b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241\u20135.","DOI":"10.1210\/jcem-64-6-1241"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_025_w2aab3b7c61b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves\u2019 disease: National Long-Term Cohort Study. J Clin Endocrinol Metab 2012;97:110\u20139.","DOI":"10.1210\/jc.2011-1944"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_026_w2aab3b7c61b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Jevalikar G, Solis J, Zacharin M. Long-term outcomes of pediatric Graves\u2019 disease. J Pediatr Endocrinol Metab 2014;27:1131\u20136.","DOI":"10.1515\/jpem-2013-0342"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_027_w2aab3b7c61b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, et al. Antithyroid drug treatment for Graves\u2019 Disease in children: a long-term retrospective study at a single institution. Thyroid 2014;24:200\u20137.","DOI":"10.1089\/thy.2012.0612"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_028_w2aab3b7c61b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817\u201326.","DOI":"10.1210\/jc.2008-0842"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_029_w2aab3b7c61b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Regueras L, Prieto P, Mu\u00f1oz-Calvo MT, Pozo J, Arguinzoniz L, et al. Endocrinological abnormalities in 1105 children and adolescents with Down syndrome [Alteraciones endocrinol\u00f3gicas en 1105 ni\u00f1os y adolescentes con s\u00edndrome de Down]. Med Clin (Barc) 2011;136:376\u201381.","DOI":"10.1016\/j.medcli.2010.06.029"},{"key":"2023040100083367651_j_jpem-2018-0132_ref_030_w2aab3b7c61b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Marin\u00f2 M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves\u2019 disease. J Endocrinol Invest 2015;38:283\u201394.","DOI":"10.1007\/s40618-014-0214-2"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2018.31.issue-7\/jpem-2018-0132\/jpem-2018-0132.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0132\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T14:07:53Z","timestamp":1680358073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0132\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,6,2]]},"published-print":{"date-parts":[[2018,7,26]]}},"alternative-id":["10.1515\/jpem-2018-0132"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2018-0132","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"type":"electronic","value":"2191-0251"},{"type":"print","value":"0334-018X"}],"subject":[],"published":{"date-parts":[[2018,6,28]]}}}